| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 6, 2006
Accepted on June 13, 2007
Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School, Tokyo 113-8519, Japan
* To whom correspondence should be addressed. E-mail: ktsuchiya.cme{at}tmd.ac.jp.
Genetic deletion of inducible nitric oxide synthase (iNOS) in mice has been shown to improve high-fat diet (HFD)-induced insulin resistance. However, a pathophysiological role of endogenous NO in obesity-related insulin resistance remains controversial. To address this issue, we examined the metabolic phenotypes in HFD-induced obese mice with chronic blockade of NO synthesis by a NOS inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME). Six-week-old male C57BL/6j mice were provided free access to either a standard diet (SD) or a HFD and to tap water with or without L-NAME (100 mg/kg/day) for 12 weeks. L-NAME treatment significantly attenuated body weight gain of mice fed either SD or HFD without affecting calorie intake. L-NAME treatment in HFD-fed mice improved glucose tolerance and insulin sensitivity. HFD feeding induced iNOS mRNA expression, but not other two NOS isoforms, in white adipose tissue (WAT) and skeletal muscle. L-NAME treatment up-regulated uncoupling protein (UCP)-1 in brown adipose tissue of HFD-fed mice, but down-regulated monocyte chemoattractant protein-1 and CD68 mRNAs levels in WAT. HFD feeding up-regulated leptin mRNA levels, but conversely down-regulated adiponectin mRNA levels in WAT, but these effects were unaffected by L-NAME treatment. Moreover, L-NAME treatment also increased peroxisome proliferator-activated receptor-
and UCP-3 mRNA levels in skeletal muscles of HFD-fed mice. Increased urinary excretion of norepinephrine after HFD feeding was augmented in L-NAME-treated mice. Insulin-stimulated tyrosine phosphorylation of insulin receptor substrate-1 and serine phosphorylation of Akt/Akt2 in soleus muscle was markedly impaired in HFD-fed mice, but reversed by L-NAME treatment. In conclusion, chronic NOS blockade by L-NAME in mice ameliorates HFD-induced adiposity and glucose intolerance, accompanied by reduced adipose inflammation and improved insulin signaling in skeletal muscle, suggesting that endogenous NO plays a modulatory role in the development of obesity-related insulin resistance.
This article has been cited by other articles:
![]() |
M. C. Moore, C. A. DiCostanzo, M. S. Smith, B. Farmer, T. D. Rodewald, D. W. Neal, P. E. Williams, and A. D. Cherrington Hepatic portal venous delivery of a nitric oxide synthase inhibitor enhances net hepatic glucose uptake Am J Physiol Endocrinol Metab, April 1, 2008; 294(4): E768 - E777. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-G. Joost and M. H. Tschop NO to Obesity: Does Nitric Oxide Regulate Fat Oxidation and Insulin Sensitivity? Endocrinology, October 1, 2007; 148(10): 4545 - 4547. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |